First-generation EGFR TKIs, including gefitinib and erlotinib, have demonstrated substantial clinical benefits in NSCLC patients harboring EGFR-activating mutations, resulting in improved progression-free survival and enhanced quality of life. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.